| Literature DB >> 35878284 |
Korawin Triyasakorn1, Ubah Dominic Babah Ubah1, Brandon Roan2, Minsyusheen Conlin3, Ken Aho3, Prabha S Awale1.
Abstract
Autism spectrum disorder (ASD), a neurodevelopmental condition affecting approximately 1 in 44 children in North America, is thought to be a connectivity disorder. Valproic acid (VPA) is a multi-target drug widely used to treat epilepsy. It is also a toxic teratogen as well as a histone deacetylase inhibitor, and fetal exposure to VPA increases the risk of ASD. While the VPA model has been well-characterized for behavioral and neuronal deficits including hyperconnectivity, microglia, the principal immune cells of CNS that regulate dendrite and synapse formation during early brain development, have not been well-characterized and may provide potential hints regarding the etiology of this disorder. Therefore, in this study, we determined the effect of prenatal exposure to VPA on microglial numbers during early postnatal brain development. We found that prenatal exposure to VPA causes a significant reduction in the number of microglia in the primary motor cortex (PMC) during early postnatal brain development, particularly at postnatal day 6 (P6) and postnatal day 10 (P10) in male mice. The early microglial reduction in the VPA model coincides with active cortical synaptogenesis and is significant because it may potentially play a role in mediating impaired connectivity in ASD.Entities:
Keywords: microglia; primary motor cortex; valproic acid
Year: 2022 PMID: 35878284 PMCID: PMC9319720 DOI: 10.3390/toxics10070379
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Figure 1VPA-treated male mice show decreases in microglial number and fragmented morphology in primary motor cortex at P6. Confocal images showing labeled microglia in the PMC of saline control and age-matched brains of VPA mouse model of autism. (a,b) Microglia labeled with Iba1 (green) in control and VPA-treated mice at low magnification (200×). (c,d) Microglia labeled with Iba1 (green) at high magnification (600×). White square region (insert) in a and b is magnified in c and d. White arrows and arrowheads indicate differences in morphology of microglia in control and VPA model. Scale bar (a,b) 200 µm and in (c,d) 50 µm. (e) Analysis of number of microglia as summarized within the bar graphs (Mean ± SEM) reveals a statistically significant decrease in microglial number in VPA-treated mice (* p = 3.7 × 10−5).
Figure 2VPA-treated male mice show significant decrease in microglial number and fragmented morphology in primary motor cortex at P10. Confocal images showing labeled microglia in cortex of saline control and age matched brains in VPA mouse model of autism. (a,b) Microglia labeled with Iba1 (green) in control mice and VPA-treated mice at low magnification (200×). (c,d) Microglia labeled with Iba1 (green) at high magnification (600×). White square region (insert) in a and b is magnified in c and d. White arrows and arrowheads indicate differences in morphology of microglia in control and VPA model. Scale bar (a,b) 200 µm and in (c,d) 50 µm. (e) Analysis of number of microglia as summarized within the bar graphs (Mean ± SEM) reveals a statistically significant decrease in microglial number in VPA-treated mice (* p = 2.3 × 10−9).